


MAXIM.078A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hellstrand et al. ) Group Art Unit: 1614  
App. No. : 09/616,622 )  
Filed : July 14, 2000 )  
For : ACTIVATION AND PROTECTION )  
OF CYTOTOXIC LYMPHOCYTES )  
USING A REACTIVE OXYGEN )  
METABOLITE INHIBITOR )  
Examiner : Unknown )

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account 11-1410. A duplicate copy of this Statement is enclosed for that purpose.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 27 NOV 2000

By: 

James J. Mullen III, Ph.D.  
Registration No. 44,957  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(619) 235-8550